Fzata Stands with IBD Community On World IBD Day https://wix.to/GaO65IG #newblogpost
Fzata, Inc.
Pharmaceutical Manufacturing
Halethorpe, Maryland 338 followers
Live Biologics in a Pill. SynBio yeast micro-factories make biologics in your GI. No more needles!
About us
Fzata, Inc. is a oral biologics biopharmaceutical company based in Halethorpe, MD within the vibrant BioHealth Capital Region. Fzata’s vision is to reduce health inequities by expanding patient access to therapeutic biologics. This is made possible with our proprietary first-in-class oral Bioengineered Probiotic Yeast Medicines (BioPYM™) platform. BioPYM enables orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI disorders like infectious diseases, inflammation, metabolic diseases, (e.g., diabetes), colon cancer, and more. Our oral biologic drug candidates are intended to help patients that inject biologic medicine by 1) offering affordable, non-refrigerated, convenient oral capsules, 2) improving quality of life with no needles and no need for health-care administration and 3) improving patient outcomes with expected high safety and high efficacy targeted to GI.
- Website
-
http://fzata.com
External link for Fzata, Inc.
- Industry
- Pharmaceutical Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Halethorpe, Maryland
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Biologics , Antibodies, Therapeutics, Nanobodies, Gastrointestinal, SYNBIO, Inflammatory Bowel Disease, C. diff Infection, Crohn's, IBD, and OralBiologic
Locations
-
Get directions
1448 S ROLLING RD
Halethorpe, Maryland 21227, US
Employees at Fzata, Inc.
-
Elizabeth Anne Smith, PhD MBA
Chief Business Officer @ Fzata, Inc. | Biotechnology Industry, Strategic Corporate Business Development. Advancing biologic therapeutics from…
-
Edward So
Scientist | Biotech
-
Sonali Kumari
Research Scientist at Fzata, Inc. | Georgetown University Alumna
-
Rachel Lee
Research Scientist at Fzata, Inc.
Updates
-
CBO, Elizabeth Smith, will be pitching at #CONNECTpreneur on Fzata's home turf, BWTECH South! This is a full circle moment for us, as we were a winner of the 2022 Mid-Atlantic Innovation Celebration for Biotechnology which is co-hosted by CONNECTpreneur. The executive team will be at the event to re-engage with old and new friends tomorrow!
-
-
Fzata, Inc. reposted this
We are thrilled at the opportunity to address industry leaders in the microbiome therapeutic & scientific communities and share our advancements on BioPYM at the #Microbiome Connect Meeting in Boston November 20 and 21, 2024. Zhiyong Yang, PhD, CEO of #Fzata, will be presenting. On the day 1 she will present "Oral Biologics Powered by Fzata’s BioPYM Platform" during the Therapeutics Breakthroughs session at 4:30 pm. On day 2, Fzata is honored to have been selected as one of three companies to present at the Biotech Preclinical Showcase at 11:30 am. We are looking forward to meeting collaborators and partners at the meeting!
-
-
We are thrilled at the opportunity to address industry leaders in the microbiome therapeutic & scientific communities and share our advancements on BioPYM at the #Microbiome Connect Meeting in Boston November 20 and 21, 2024. Zhiyong Yang, PhD, CEO of #Fzata, will be presenting. On the day 1 she will present "Oral Biologics Powered by Fzata’s BioPYM Platform" during the Therapeutics Breakthroughs session at 4:30 pm. On day 2, Fzata is honored to have been selected as one of three companies to present at the Biotech Preclinical Showcase at 11:30 am. We are looking forward to meeting collaborators and partners at the meeting!
-
-
The #PODD2024 Soap Box presentation was delivered to a FULL HOUSE. At least 1,000, with all the top pharma represented. The cutting-edge #Fzata oral biologics message was new to this group. Welp, we are in this business for the patients. Oral biologics are coming. Injectables better get ready for a sea change in administration route!
-
-
Chief Business Officer @ Fzata, Inc. | Biotechnology Industry, Strategic Corporate Business Development. Advancing biologic therapeutics from start-up to clinic.
Had a great experience at Mini Pitch Day Oct 16 hosted by #NYBIO at the beautiful #WilmerHale Offices in NYC. Sorry the view is not so spectacular in the photo. Fabulous audience and great feed-back and questions on the #Fzata oral biologics platform and FZ006 for #IBD. Thank you for the support of the biotech early-stage community. Priyanka Shah, props for super great insights!
-
-
We are honored to have been selected with these other great companies as a "Biopharma Industry Mover". We are getting closer everyday to making oral biologics a reality. Our mission is to transform patient safety, efficacy & access to biologics with BioPYM yeast micro-factories.
Featured highlights from today's Efortless Update: [Clinical Trials] 09/25 Gen's phase 2 Trial Shows GN-037 Cream Reduces Psoriasis Symptoms in 190 Patients 09/25 Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT)' phase 3 trials show ZORYVE cream 0.15% consistently treats atopic dermatitis symptoms across racial, ethnic, and skin-type subgroups same day : ( ↓ NASDAQ: ARQT | -1.24% ) 09/25 Merck's KEYFORM-007 Trial Fails to Meet Primary Endpoint in Metastatic Colorectal Cancer Treatment same day : ( ↑ NYSE: MRK | +0.47% ) 09/25 Kyowa Kirin Co., Ltd. Reports phase 3 Trial Success of Rocatinlimab for Atopic Dermatitis 09/25 Windtree Therapeutics, Inc.' phase 2b SEISMiC Study Reveals Istaroxime Increase in Systolic Blood Pressure in Cardiogenic Shock Patients same day : ( ↓ NASDAQ: WINT | -7.98% ) [Deals] 09/25 Bayer, Asklepios BioPharmaceutical, Inc. (AskBio), and Belief BioMed collaborate to explore liver-targeted gene therapies using BBM's next-gen capsid technology 09/25 Orion Innovation and Aitia Partner for $10M-per-drug-target Cancer Discovery, Melding Digital Twins and AI with Pre-clinical Data 09/24 Fzata, Inc. receives $7M UG3/UH3 grant from The National Institutes of Health National Institute of Neurological Disorders and Stroke for Development of FZ006 in collaboration with University of Maryland, Baltimore (UMB), Baltimore 09/24 Coegin Pharma AB and Scandinavian Biolabs to Develop Hair Growth Products Using FOL005, Set to Launch in 2025 [Venture Capital] 09/25 Genespire secures €46.6 million in Series B funding for phase I/II trials of pediatric gene therapy GENE202 for Methylmalonic Acidemia [Regulatory] 09/25 IntraBio Inc receives FDA approval for AQNEURSA to treat Niemann-Pick disease type C following clinical trial 09/25 Elixirgen Therapeutics, Inc. initiates phase 1/2 trial of EXG-34217 for telomere biology disorders at Cincinnati Children’s Hospital Medical Center 09/24 European Commission approves toripalimab for treatment of two cancer types based on JUPITER-02 and JUPITER-06 studies results View the full newsletter contents for free via the link in the comments.
-
-
Breaking news! Fzata has been selected for a “Soapbox Presentation” at the upcoming 14th Annual Partnership Opportunities in Drug Delivery (#PODD2024) conference, Oct 28-29 in Boston. I’m looking forward to speaking on our game changing BioPYM oral platform for biologics delivery. Patient-friendly BioPYM fills a huge gap in oral non-injectable technologies for biologics. I can’t wait to share our IND stage development with the big pharma crowd! #drugdelivery #partnershipopportunities #drugdevelopment #pharma